|
Segment, Product and Geographic Area Information - Revenues By Products (Detail) (USD $)
In Millions |
3 Months Ended | 6 Months Ended | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jul. 03, 2011
|
Jul. 04, 2010
|
Jul. 03, 2011
|
Jul. 04, 2010
|
|||||||||||
| Revenue from External Customer [Line Items] | ||||||||||||||
| Revenues | $ 16,984 | $ 17,132 | $ 33,486 | $ 33,708 | ||||||||||
|
Biopharmaceutical [Member]
|
||||||||||||||
| Revenue from External Customer [Line Items] | ||||||||||||||
| Revenues | 14,640 | 15,021 | 28,864 | 29,527 | ||||||||||
|
Biopharmaceutical [Member] | Lipitor [Member]
|
||||||||||||||
| Revenue from External Customer [Line Items] | ||||||||||||||
| Revenues | 2,591 | 2,813 | 4,976 | 5,570 | ||||||||||
|
Biopharmaceutical [Member] | Prevnar / Prevenar 13 [Member]
|
||||||||||||||
| Revenue from External Customer [Line Items] | ||||||||||||||
| Revenues | 821 | 569 | 1,817 | 855 | ||||||||||
|
Biopharmaceutical [Member] | Enbrel [Member]
|
||||||||||||||
| Revenue from External Customer [Line Items] | ||||||||||||||
| Revenues | 914 | [1] | 808 | [1] | 1,784 | [1] | 1,610 | [1] | ||||||
|
Biopharmaceutical [Member] | Lyrica [Member]
|
||||||||||||||
| Revenue from External Customer [Line Items] | ||||||||||||||
| Revenues | 908 | 762 | 1,734 | 1,485 | ||||||||||
|
Biopharmaceutical [Member] | Celebrex [Member]
|
||||||||||||||
| Revenue from External Customer [Line Items] | ||||||||||||||
| Revenues | 622 | 604 | 1,213 | 1,174 | ||||||||||
|
Biopharmaceutical [Member] | Viagra [Member]
|
||||||||||||||
| Revenue from External Customer [Line Items] | ||||||||||||||
| Revenues | 495 | 491 | 965 | 970 | ||||||||||
|
Biopharmaceutical [Member] | Norvasc [Member]
|
||||||||||||||
| Revenue from External Customer [Line Items] | ||||||||||||||
| Revenues | 375 | 422 | 731 | 790 | ||||||||||
|
Biopharmaceutical [Member] | Xalatan / Xalacom [Member]
|
||||||||||||||
| Revenue from External Customer [Line Items] | ||||||||||||||
| Revenues | 291 | 449 | 683 | 871 | ||||||||||
|
Biopharmaceutical [Member] | Zyvox [Member]
|
||||||||||||||
| Revenue from External Customer [Line Items] | ||||||||||||||
| Revenues | 325 | 299 | 644 | 591 | ||||||||||
|
Biopharmaceutical [Member] | Sutent [Member]
|
||||||||||||||
| Revenue from External Customer [Line Items] | ||||||||||||||
| Revenues | 296 | 255 | 572 | 514 | ||||||||||
|
Biopharmaceutical [Member] | Premarin family [Member]
|
||||||||||||||
| Revenue from External Customer [Line Items] | ||||||||||||||
| Revenues | 255 | 260 | 490 | 516 | ||||||||||
|
Biopharmaceutical [Member] | Geodon / Zeldox [Member]
|
||||||||||||||
| Revenue from External Customer [Line Items] | ||||||||||||||
| Revenues | 258 | 247 | 490 | 501 | ||||||||||
|
Biopharmaceutical [Member] | Detrol / Detrol LA [Member]
|
||||||||||||||
| Revenue from External Customer [Line Items] | ||||||||||||||
| Revenues | 230 | 260 | 455 | 521 | ||||||||||
|
Biopharmaceutical [Member] | Genotropin [Member]
|
||||||||||||||
| Revenue from External Customer [Line Items] | ||||||||||||||
| Revenues | 230 | 233 | 439 | 439 | ||||||||||
|
Biopharmaceutical [Member] | Chantix / Champix [Member]
|
||||||||||||||
| Revenue from External Customer [Line Items] | ||||||||||||||
| Revenues | 190 | 170 | 389 | 359 | ||||||||||
|
Biopharmaceutical [Member] | Vfend [Member]
|
||||||||||||||
| Revenue from External Customer [Line Items] | ||||||||||||||
| Revenues | 192 | 207 | 387 | 395 | ||||||||||
|
Biopharmaceutical [Member] | Effexor XR [Member]
|
||||||||||||||
| Revenue from External Customer [Line Items] | ||||||||||||||
| Revenues | 168 | 621 | 372 | 1,337 | ||||||||||
|
Biopharmaceutical [Member] | Zosyn / Tazocin [Member]
|
||||||||||||||
| Revenue from External Customer [Line Items] | ||||||||||||||
| Revenues | 162 | 230 | 341 | 494 | ||||||||||
|
Biopharmaceutical [Member] | BeneFIX [Member]
|
||||||||||||||
| Revenue from External Customer [Line Items] | ||||||||||||||
| Revenues | 176 | 164 | 340 | 318 | ||||||||||
|
Biopharmaceutical [Member] | Prevnar / Prevenar (7-valent) [Member]
|
||||||||||||||
| Revenue from External Customer [Line Items] | ||||||||||||||
| Revenues | 155 | 331 | 308 | 851 | ||||||||||
|
Biopharmaceutical [Member] | Caduet [Member]
|
||||||||||||||
| Revenue from External Customer [Line Items] | ||||||||||||||
| Revenues | 143 | 126 | 285 | 261 | ||||||||||
|
Biopharmaceutical [Member] | Zoloft [Member]
|
||||||||||||||
| Revenue from External Customer [Line Items] | ||||||||||||||
| Revenues | 146 | 144 | 281 | 264 | ||||||||||
|
Biopharmaceutical [Member] | Pristiq [Member]
|
||||||||||||||
| Revenue from External Customer [Line Items] | ||||||||||||||
| Revenues | 147 | 113 | 276 | 223 | ||||||||||
|
Biopharmaceutical [Member] | Medrol [Member]
|
||||||||||||||
| Revenue from External Customer [Line Items] | ||||||||||||||
| Revenues | 135 | 113 | 256 | 222 | ||||||||||
|
Biopharmaceutical [Member] | Revatio [Member]
|
||||||||||||||
| Revenue from External Customer [Line Items] | ||||||||||||||
| Revenues | 130 | 122 | 253 | 236 | ||||||||||
|
Biopharmaceutical [Member] | Zithromax / Zmax [Member]
|
||||||||||||||
| Revenue from External Customer [Line Items] | ||||||||||||||
| Revenues | 114 | 110 | 242 | 213 | ||||||||||
|
Biopharmaceutical [Member] | ReFacto AF/ Xyntha [Member]
|
||||||||||||||
| Revenue from External Customer [Line Items] | ||||||||||||||
| Revenues | 123 | 98 | 240 | 188 | ||||||||||
|
Biopharmaceutical [Member] | Aromasin [Member]
|
||||||||||||||
| Revenue from External Customer [Line Items] | ||||||||||||||
| Revenues | 95 | 122 | 209 | 250 | ||||||||||
|
Biopharmaceutical [Member] | Aricept [Member]
|
||||||||||||||
| Revenue from External Customer [Line Items] | ||||||||||||||
| Revenues | 106 | [2] | 103 | [2] | 205 | [2] | 210 | [2] | ||||||
|
Biopharmaceutical [Member] | Cardura [Member]
|
||||||||||||||
| Revenue from External Customer [Line Items] | ||||||||||||||
| Revenues | 101 | 110 | 197 | 217 | ||||||||||
|
Biopharmaceutical [Member] | BMP2 [Member]
|
||||||||||||||
| Revenue from External Customer [Line Items] | ||||||||||||||
| Revenues | 101 | 99 | 194 | 197 | ||||||||||
|
Biopharmaceutical [Member] | Rapamune [Member]
|
||||||||||||||
| Revenue from External Customer [Line Items] | ||||||||||||||
| Revenues | 100 | 97 | 189 | 188 | ||||||||||
|
Biopharmaceutical [Member] | Fragmin [Member]
|
||||||||||||||
| Revenue from External Customer [Line Items] | ||||||||||||||
| Revenues | 97 | 84 | 188 | 174 | ||||||||||
|
Biopharmaceutical [Member] | Tygacil [Member]
|
||||||||||||||
| Revenue from External Customer [Line Items] | ||||||||||||||
| Revenues | 75 | 88 | 148 | 172 | ||||||||||
|
Biopharmaceutical [Member] | Protonix [Member]
|
||||||||||||||
| Revenue from External Customer [Line Items] | ||||||||||||||
| Revenues | 44 | 174 | 103 | 332 | ||||||||||
|
Biopharmaceutical [Member] | Alliance revenues [Member]
|
||||||||||||||
| Revenue from External Customer [Line Items] | ||||||||||||||
| Revenues | 875 | [3] | 1,061 | [3] | 1,759 | [3] | 2,065 | [3] | ||||||
|
Biopharmaceutical [Member] | All Other Biopharmaceutical Products [Member]
|
||||||||||||||
| Revenue from External Customer [Line Items] | ||||||||||||||
| Revenues | 2,454 | 2,062 | 4,709 | 3,954 | ||||||||||
|
Other products [Member] | Animal Health [Member]
|
||||||||||||||
| Revenue from External Customer [Line Items] | ||||||||||||||
| Revenues | 1,055 | 893 | 2,037 | 1,739 | ||||||||||
|
Other products [Member] | Consumer Healthcare [Member]
|
||||||||||||||
| Revenue from External Customer [Line Items] | ||||||||||||||
| Revenues | 721 | 678 | 1,466 | 1,341 | ||||||||||
|
Other products [Member] | Nutrition [Member]
|
||||||||||||||
| Revenue from External Customer [Line Items] | ||||||||||||||
| Revenues | 493 | 476 | 963 | 934 | ||||||||||
|
Other products [Member] | Pfizer CentreSource [Member]
|
||||||||||||||
| Revenue from External Customer [Line Items] | ||||||||||||||
| Revenues | $ 75 | $ 64 | $ 156 | $ 167 | ||||||||||
|
||||||||||||||